• The Trump administration is considering Section 232 tariffs of up to 25%—or higher—on imported pharmaceuticals and ingredients, citing national security concerns.
  • Industry analysts warn of supply chain disruptions and higher drug prices, with potential ripple effects across global trade relations.
  • The move signals a broader push to reshore critical manufacturing, but faces opposition from healthcare advocates and pharmaceutical firms.

Section 232 Probe Targets Pharma Imports

The Trump administration has launched a Section 232 investigation into U.S. imports of pharmaceuticals and active ingredients, a move that could lead to sweeping tariffs on drugs and their components. Peter Navarro, recently appointed as Senior Counselor for Trade and Manufacturing, confirmed the administration’s intent to use national security provisions to justify the measures, with rates potentially reaching 25% or higher—though President Trump has floated figures as steep as 200% in public remarks.

Industry Braces for Cost Hikes and Disruptions

The proposed tariffs would hit a sector already grappling with global supply chain fragility and domestic pricing pressures. Major U.S. pharma firms like Pfizer, Merck, and Johnson & Johnson rely heavily on imported ingredients, particularly from China and India. A 25% levy could force manufacturers to either absorb costs—squeezing margins—or pass them on to consumers, exacerbating existing concerns over drug affordability.

“This isn’t just about tariffs; it’s about reconfiguring entire supply chains,” said one industry executive, speaking anonymously due to the sensitivity of ongoing negotiations. “Reshoring production isn’t something that happens overnight.”

Trade Tensions and Legal Challenges Loom

The use of Section 232—traditionally reserved for sectors like steel and aluminum—marks an unprecedented expansion of trade powers into healthcare. Analysts predict fierce pushback from trading partners, including the EU and India, with potential retaliatory measures. Legal challenges are also likely, mirroring disputes over earlier Section 232 actions.

While the administration frames the probe as a bid to reduce reliance on foreign suppliers, critics argue it could backfire. “Tariffs won’t magically rebuild U.S. API [active pharmaceutical ingredient] capacity,” noted a healthcare policy analyst. “In the short term, this risks shortages and price spikes for critical medications.”

Correction: An earlier version misstated the potential tariff ceiling. While 25% is under formal consideration, President Trump has publicly suggested rates could go significantly higher.